What was the recent good news for SEEL stock

Seelos Therapeutics (SEEL) recently announced the pricing of a registered direct offering and concurrent private placement, which was priced at-the-market under Nasdaq rules. The offering provided for the purchase and sale of 380,968 shares of common stock and pre-funded warrants to purchase up to 81,239 shares of common stock at a price of $2.46 per share. This news could be seen as positive as it indicates that the company has successfully raised capital through a financing round, which could be used to further develop its therapies or for general corporate purposes.